Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project. NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied.Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator.Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved. To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables. 2) To assess the effect of theophylline on previous molecular, functional and clinical data. Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization. NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays. These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function
| Condition | Intervention |
|---|---|
|
COPD |
Drug: Theophylline |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline |
- HDAC activity in alveolar macrophages [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Lung function [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Inflammatory cytokine release in sputum and serum [ Time Frame: 3 months ] [ Designated as safety issue: No ]
| Enrollment: | 35 |
| Study Start Date: | June 2005 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Low-dose theophylline on top of standard therapy for COPD exacerbation
|
Drug: Theophylline
Theophylline 100 mg bid for 3 months
|
|
No Intervention: 2
Standard therapy for COPD exacerbation
|
Eligibility| Ages Eligible for Study: | 40 Years to 75 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Severe COPD according to GOLD guidelines
- Age between 40 and 75
- Admission to hospital due to COPD exacerbation
Exclusion Criteria:
- History of asthma
- Pulmonary embolism
- Pneumonia
- Other chronic inflammatory disease
- Patient on theophylline at the time of admission
- Patient on oral steroids at the time of admission
Contacts and Locations| Spain | |
| Hospital Universitario Son Dureta | |
| Palma de Mallorca, Baleares, Spain, 07014 | |
| Principal Investigator: | Borja G Cosio, MD | Hospital Universitario Son Dureta |
More Information
Publications:
| Responsible Party: | Borja G Cosio MD, Specialist in Respiratory Medicine |
| ClinicalTrials.gov Identifier: | NCT00671151 History of Changes |
| Other Study ID Numbers: | FIS042146 |
| Study First Received: | April 30, 2008 |
| Last Updated: | May 2, 2008 |
| Health Authority: | Spain: Ethics Committee |
Keywords provided by Hospital Universitari Son Dureta:
|
COPD exacerbation histone steroid resistance inflammation theophylline |
Additional relevant MeSH terms:
|
Lung Diseases Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases Theophylline Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
Physiological Effects of Drugs Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Phosphodiesterase Inhibitors Enzyme Inhibitors Vasodilator Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 19, 2013